<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03207295</url>
  </required_header>
  <id_info>
    <org_study_id>2017-898</org_study_id>
    <nct_id>NCT03207295</nct_id>
  </id_info>
  <brief_title>Impact of Nesiritide on Early Postoperative Recovery After Total Cavo-Pulmonary Connection Surgery in Children</brief_title>
  <official_title>A Randomized, Single-Blind, Placebo-Controlled, Single-Center Clinical Study of the Efficacy and Safety of Nesiritide on Early Postoperative Recovery After Total Cavo-Pulmonary Connection Surgery in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibet Kang Zhe Pharmaceutical Technology Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nesiritide, a recombinant human B-type natriuretic peptide, has favorable effects on patient&#xD;
      symptoms, hemodynamics, and the neurohumoral profile in adults with decompensated congestive&#xD;
      heart failure and in those recovering from cardiac surgery involving cardiopulmonary bypass.&#xD;
      Investigators seek to determine whether nesiritide would improve the early postoperative&#xD;
      course after total cavo-pulmonary connection surgery in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: This study aims to evaluate the efficacy and safety of nesiritide after total&#xD;
      cavo-pulmonary connection surgery in children. Investigators hypothesized that compared with&#xD;
      placebo, patients assigned to receive nesiritide will improve early postoperative outcomes.&#xD;
      Study design: The study is a a single-center, randomized, single-blinded, placebo-controlled,&#xD;
      two-arm parallel-group clinical trial, patients undergoing total cavo-pulmonary connection&#xD;
      surgery are assigned to receive nesiritide or placebo. A standard dose of study drug was&#xD;
      administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care&#xD;
      unit admission. The primary outcome is days of chest drainage. Secondary outcomes included&#xD;
      days of hospitalization measures of cardiovascular function, renal function, and adverse&#xD;
      events and neurohumoral. The eligible participants will be allocated into intervention and&#xD;
      control groups in a 1:1 ratio randomly. The intervention group will receive study drug. All&#xD;
      the participants will be followed up during hospitalization .&#xD;
&#xD;
      Statistical analysis: Evaluation will be carried out on an intention-to-treat basis. Values&#xD;
      of analyzed endpoints between intervention group and control group will be compared according&#xD;
      to the analysis plan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of chest drainage</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>Investigators will measure the daily chest drainage flow before discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization after surgery</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Postoperative hospital days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative early survival</measure>
    <time_frame>The 30th day after surgery</time_frame>
    <description>Number of days alive within 30 days of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of heart rate</measure>
    <time_frame>Baseline; Up to 20 weeks</time_frame>
    <description>Investigators will measure the heart rate twice a day(Unit :beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of heart rhythm</measure>
    <time_frame>Baseline; Up to 20 weeks</time_frame>
    <description>Investigators will measure the heart rhythm twice a day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of blood pressure</measure>
    <time_frame>Baseline; Up to 20 weeks</time_frame>
    <description>Investigators will measure the blood pressure twice a day(Units :mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of central venous pressure</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Investigators will measure the central venous pressure(Unit :cmH2O)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of liquid volume</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Investigators will measure the liquid volume each day after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of creatinine</measure>
    <time_frame>Baseline; 1 day before using nesiritide; day 1 day 3 day 5 day 7 after using nesiritide;</time_frame>
    <description>Investigators will measure the creatinine(Unit :umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of blood urea nitrogen</measure>
    <time_frame>Baseline; 1 day before using nesiritide; day 1 day 3 day 5 day 7 after using nesiritide;</time_frame>
    <description>Investigators will measure the blood urea nitrogen(Unit :mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of glutamic oxalacetic transaminase</measure>
    <time_frame>Baseline; 1 day before using nesiritide; day 1 day 3 day 5 day 7 after using nesiritide</time_frame>
    <description>Investigators will measure the glutamic oxalacetic transaminase(Unit :U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of glutamic pyruvate transaminase</measure>
    <time_frame>Baseline; 1 day before using nesiritide; day 1 day 3 day 5 day 7 after using nesiritide</time_frame>
    <description>Investigators will measure the glutamic pyruvate transaminase(Unit :U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of total bilirubin</measure>
    <time_frame>Baseline; 1 day before using nesiritide; day 1 day 3 day 5 day 7 after using nesiritide</time_frame>
    <description>Investigators will measure the total bilirubin(Unit :umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of N-terminal pro B-type natriuretic peptide</measure>
    <time_frame>Baseline; 1 day before using nesiritide; day 1 day 3 day 5 day 7 after using nesiritide</time_frame>
    <description>Investigators will measure the N-terminal pro B-type natriuretic peptide(Unit :pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of endothelin</measure>
    <time_frame>Baseline; 1 day before using nesiritide; day 1 day 3 day 5 day 7 after using nesiritide</time_frame>
    <description>Investigators will measure the endothelin(Unit :ng/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Total Cavo-pulmonary Connection</condition>
  <arm_group>
    <arm_group_label>Intervention-Nesiritide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nesiritide</intervention_name>
    <description>A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission</description>
    <arm_group_label>Intervention-Nesiritide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children</description>
    <arm_group_label>Control-Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Elective general anesthesia down Fontan surgery patients, postoperative retention of&#xD;
             patients with thoracic drainage tube&#xD;
&#xD;
          2. Age ≤ 14 years old between hospitalized patients, men and women are not limited&#xD;
&#xD;
          3. Postoperative hospital stay&gt; 7 days&#xD;
&#xD;
          4. Patients or guardians voluntarily signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Before the group had serious head trauma need hospitalization or brain surgery&#xD;
             patients&#xD;
&#xD;
          2. Who received organ transplants&#xD;
&#xD;
          3. Preoperative 48 hours application of recombinant B-type natriuretic peptide drugs&#xD;
&#xD;
          4. Preoperative cardiogenic shock or hypotension difficult to correct the patient&#xD;
&#xD;
          5. Preoperative patients with active arrhythmia&#xD;
&#xD;
          6. Preoperative serum creatinine&gt; 1.5mg / dl or need dialysis patients&#xD;
&#xD;
          7. Preoperative liver dysfunction (glutamic oxalacetic transaminase /glutamic pyruvate&#xD;
             transaminase elevated normal high 3 times or more)&#xD;
&#xD;
          8. Failed Fontan patients requiring secondary surgery&#xD;
&#xD;
          9. Patients with allergic to Nesiritide&#xD;
&#xD;
         10. The researchers believe that should not participate in the entry of patients&#xD;
&#xD;
         11. 3 months before the trial participated in other clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Yajuan, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China National Center for Cardiovascular Disease</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Duan Yabing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China National Center for Cardiovascular Disease</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Jun, MD,PhD</last_name>
    <phone>13701025206</phone>
    <email>yanjun.1112@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Jun, MD,PhD</last_name>
      <email>yanjun.1112@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nesiritide</keyword>
  <keyword>Total Cavo-Pulmonary Connection</keyword>
  <keyword>Congenital Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Consent for sharing of non identifiable study data for regulatory authorities</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

